基于dihydromyricetin的食补充剂在与代谢功能障碍相关的脂肪性肝病中:双盲,安慰剂控制,随机的临床试验
Εlisavet Michailidou1, Stavros P Papadakos1, Εleni Κoukoulioti2
11 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).
Annals of gastroenterology
|January 30, 2026
概括
一种二米瑞 (DHM) 补充剂改善了代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的肝酶和硬度. 这种DHM配方也对糖尿病和脂质概况产生了积极的影响,这需要进一步调查.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 越来越普遍,但有效的治疗方法仍然有限.
- 饮食干预对于管理MASLD进展和相关的代谢并发症至关重要.
研究的目的:
- 评估含有二米瑞 (DHM) 的食补充剂在改善成人 MASLD 患者的肝脏健康和代谢参数方面的疗效.
- 评估DHM补充对肝酶,肝硬度和血糖/脂质概况的影响.
主要方法:
- 一个为期12个月的随机对照试验,涉及成年MASLD患者.
- 参与者接受了DHM,维生素C/E和胆补充剂 (A组) 或安慰剂 (B组).
- 每六个月评估一次临床,实验室参数和肝硬度测量 (LSM).
主要成果:
- 在6个月和12个月后,二米瑞 (DHM) 补充剂导致肝酶 (ALT/GGT) 和肝硬度测量 (LSM) 的显著降低.
- 与安慰剂相比,A组患者的ALT/GGT正常化率显著更高 (35%与5%相比,P=0.028).
- 在MASLD患者中,DHM补充与葡萄糖,HbA1c和脂质配置文件的显著改善有关.
结论:
- 在6-12个月的DHM含有补充剂疗程中,MASLD患者的肝酶和LSM有所改善.
- 补充DHM也积极影响了糖尿病和脂质参数,表明多方面的好处.
- 建议对这种DHM补充剂进行进一步的临床评估,以对MASLD进行管理.
相关概念视频
Blind Procedures
13.4K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.4K
The Placebo Effect
6.8K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.8K
Clinical Trials
10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview
4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Statistical Software for Data Analysis and Clinical Trials
1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Diseases of the Liver and Gallbladder
2.0K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.0K


